Kathleen Ludwig, M.D. Associate Professor School Medical School Department Pediatrics You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Dr. Ludwig is a board-certified pediatric oncologist, with a special interest in the care of patients with leukemia, lymphoma, relapsed leukemia, or lymphadenopathy, as well as managing general pediatric oncology disorders. She also devotes a dedicated part of her practice to treating patients with vascular anomalies. She is an active member of the Children’s Oncology Group and serves as the institutional principal investigator for numerous early phase I trials aiming to improve survival in patients with refractory/relapsed leukemia. Dr. Ludwig feels that families play a vital role in the care of a child with cancer and works with them to provide the best, most informed care possible. Education Medical School Loyola University Chicago Stritch School of Medicine (2009) Residency UT Southwestern/Children's Medical Center (2012), Pediatrics Fellowship UT Southwestern/Children's Medical Center (2015), Pediatric Hematology/oncology Research Interest Leukemia Vascular Anomalies Publications Featured Publications Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA-related Disorders. Kolitz E, Fernandes NJ, Agim NG, Ludwigl K, J Pediatr Hematol Oncol 2022 Feb Recent progress in the treatment of cancer in children. Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch TW, CA Cancer J Clin 2021 Apr Giant Congenital Melanocytic Nevus Treated With Trametinib. Mir A, Agim NG, Kane AA, Josephs SC, Park JY, Ludwig K Pediatrics 2019 Feb Small molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer. Ludwig KF, Du W, Sorrelle N, Wnuk-Lipinska K, Topalovski M, Toombs JE, Cruz VH, Yabuuchi S, Rajeshkumar NV, Maitra A, Lorens JB, Brekken RA Cancer Res. 2017 Nov A New Case and Review of Chylothorax in Generalized Lymphatic Anomaly and Gorham-Stout Disease. Ludwig KF, Slone T, Cederberg KB, Silva AT, Dellinger M Lymphology 2016 Jun 49 2 73-84 Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA Cancer Res. 2015 Jul Results 1-6 of 6 1 Honors & Awards Best Pediatric SubspecialistD-Magazine (2021-2023) Best Poster awardUT Southwestern Pediatric Fellow's Research Symposium (2015) Best Basic Science AwardAnnual Surgical Research Forum, UT Southwestern (2014) Above-and-Beyond Recognition for ExcellenceUT Southwestern Pediatric Residency Program (2010) Professional Associations/Affiliations American Society of Clinical Oncology (2013) American Society of Hematology (2013) American Society of Pediatric Hematology/Oncology (2013) Childrens Medical Center Oncology Group (2013)
